Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon and OPDC Sign Collaboration Agreement

Published: Friday, July 25, 2014
Last Updated: Friday, July 25, 2014
Bookmark and Share
Horizon CombinatoRx to perform in-vitro cell line screening of OPDC clinical stage development candidates.

Horizon Discovery Group plc has announced that its Horizon CombinatoRx division has been contracted by Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) to perform in vitro cell line screening of certain OPDC development candidate(s).

Pursuant to the terms of the contract, Horizon CombinatoRx will be paid $835,000 for work to be substantially completed during 2014.

Horizon Discovery completed the acquisition of the CombinatoRx service business and assets from Zalicus Inc. in June 2014. Horizon CombinatoRx provides its partners access to the unique cHTS platform and Chalice™ analytics software, which enable the screening and analysis of thousands of complementary drug combinations.

Combined with Horizon’s GENESIS™ (rAAV, CRISPR and ZFN) gene editing platform and X-MAN™ isogenic cell line technology, the company offers services including novel phenotypic cell-based screens with compound siRNA, shRNA and sgRNA (for CRISPR based screening) libraries.

Dr Darrin M Disley, Chief Executive Officer of Horizon Discovery Group plc, commented: “The contract with OPDC represents the continued commercial traction of the CombinatoRx business following the acquisition which was in line with the strategy outlined at the time of Horizon’s IPO. We are delighted that OPDC has chosen to work with us on these screening projects.”

Edwin Rock, M.D., Ph.D., Senior Director, Global Clinical Development, OPDC, said: “As combination therapies emerge as the standard of care in a range of indications, it is important that we identify effective multi-target mechanisms. Using the Horizon CombinatoRx platform to explore our clinical stage programs in the context of combinations may provide us with information to guide development.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon and Redx Sign Cancer Research Collaboration
Collaboration to progress Redx Pharma plc’s novel pan-RAF inhibitor program towards out-licensing.
Friday, September 04, 2015
CareDx and Horizon Enter into a Collaboration
Horizon’s standards to support proficiency testing of CareDx solid organ transplantation injury monitoring diagnostic assay.
Thursday, June 04, 2015
Horizon Discovery Appoints Mr Grahame Cook as a Non-Executive Director
Grahame brings over 20 years’ experience to Horizon.
Thursday, May 14, 2015
Transgenomic to Incorporate Horizon's Genomic Reference Standards
Horizon to provide human genomic reference standards to assure quality and performance of Transgenomic’s Multiplexed ICE COLD-PCR kits.
Thursday, April 23, 2015
Horizon Discovery & Thermo Agreement
Horizon Discovery Group plc and Thermo Fisher Scientific sign supply and commercialization agreement, which will see Thermo market and distribute Horizon’s X-MAN cell line collection.
Monday, April 20, 2015
Horizon and Partners Awarded Up to £6.2M Funding
Horizon to receive up to £652,000 to expand bioproduction research.
Thursday, March 26, 2015
Horizon Discovery Group plc and ArcherDX Sign OEM Agreement
Horizon’s Reference Materials chosen by ArcherDX to validate its FusionPlex test for non-small cell lung cancer markers.
Tuesday, March 24, 2015
Horizon Discovery Group plc Named Business of the Year at Business Weekly Awards
Horizon joins select group of companies to receive award for a second time.
Wednesday, March 18, 2015
Horizon to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Friday, March 13, 2015
Horizon Discovery Group to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Wednesday, March 11, 2015
Horizon, Centre for Process Innovation, & University of Manchester Awarded £1.67M Innovate UK Funding
Consortium to receive funding to develop enhanced biomanufacturing platforms based on the Company’s CHO cell line and gene editing platform.
Wednesday, February 18, 2015
Horizon Discovery Group Selected as Core Facility by Tri-Institutional Therapeutics Discovery Institute
Two year master services agreement signed with an initial work order for $500,000 to carry out drug combination screening and in vitro assay development.
Monday, February 02, 2015
Horizon Discovery CEO Darrin Disley wins Entrepreneur of the Year
Darrin Disley, CEO of Horizon Discovery, wins Entrepreneur of the Year award at the Quoted Company Awards 2015.
Thursday, January 29, 2015
Horizon Discovery Group plc Trading Update
Revenues expected to be ahead of consensus by approximately 7% driven by an increased global demand for expanded product, service and IP offering.
Monday, January 19, 2015
Horizon Discovery Group plc Acquires Haplogen Genomics GmbH
Strategic acquisition of high-throughput functional genomics platform aims to drive product development, revenue growth and enable broader market penetration.
Thursday, January 08, 2015
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!